Evidence-based guideline: treatment of painful diabetic neuropathy--report of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation.

The objective of this report was to develop a scientifically sound and clinically relevant evidence-based guideline for the treatment of painful diabetic neuropathy (PDN). The basic question that was asked was: "What is the efficacy of a given treatment (pharmacological: anticonvulsants, antidepressants, opioids, others; non-pharmacological: electrical stimulation, magnetic field treatment, low-intensity laser treatment, Reiki massage, others) to reduce pain and improve physical function and quality of life (QOL) in patients with PDN?" A systematic review of literature from 1960 to August 2008 was performed, and studies were classified according to the American Academy of Neurology classification of evidence scheme for a therapeutic article. Recommendations were linked to the strength of the evidence. The results indicate that pregabalin is established as effective and should be offered for relief of PDN (Level A). Venlafaxine, duloxetine, amitriptyline, gabapentin, valproate, opioids (morphine sulfate, tramadol, and oxycodone controlled-release), and capsaicin are probably effective and should be considered for treatment of PDN (Level B). Other treatments have less robust evidence, or the evidence is negative. Effective treatments for PDN are available, but many have side effects that limit their usefulness. Few studies have sufficient information on their effects on function and QOL.

Electrodiagnostic findings and surgical outcome in isolated first branch lateral plantar neuropathy: a case series with literature review.

Two patients with recalcitrant unilateral heel pain and plantar fasciitis were referred for electrodiagnostic evaluation. They both reported constant, sharp, unilateral medial heel pain, with nocturnal symptoms, as well as exacerbation by weight-bearing activities. Examination of both patients demonstrated focal medial heel tenderness and a Tinel sign over the tarsal tunnel on the affected side. Neither patient had weakness or sensory deficits in the affected foot. In both patients, findings on nerve conduction studies were normal in the affected foot, including the first branch of the lateral plantar nerve (FBLPN), as well as the medial and lateral plantar motor and sensory (ie, mixed nerve) responses. Needle electromyographic (EMG) abnormalities were found only in the abductor digiti quinti pedis (ADQP), an intrinsic foot muscle that is exclusively innervated by the FBLPN, but there were no EMG abnormalities noted in the medial or lateral plantar-innervated muscles studied, nor the contralateral ADQP. Both patients then underwent surgical decompression of the FBLPN. Postoperative follow-up (patient 1 at 10 months, patient 2 at 21 months) revealed excellent outcomes, as defined by symptom resolution, in both patients. Electrodiagnostic evaluation was useful in diagnosing isolated first branch lateral plantar neuropathy.

Amputee Subject Testing Protocol, Results, and Analysis of a Powered Transtibial Prosthetic Device.

A powered ankle-foot prothesis and its control system were previously designed and built. To evaluate this prosthesis, amputee subject testing was performed. The testing results are analyzed and compared between the powered prosthesis, passive prosthesis, and able-bodied gait. Qualitative comparison showed the prosthesis achieved the design objectives. During stance phase, active ankle moment was generated in the powered prosthesis before push-off to help the amputee walk more naturally. During swing phase, the powered prosthesis was able to move to natural position to achieve foot clearance. However, the prosthesis is slightly under powered compared with the able-bodied ankle.